Immunity and protection following an H5N1-based polyanhydride nanoparticle IAV vaccine 4152

Frederick Tei-Maya; Payton Kahl; Chris Lopez; Kathleen Ross; Jeffery Dubert; Boopathi Sownthirarajan; Balaji Narasimhan; Balaji Manicassamy; Kevin L. Legge

doi:10.1093/jimmun/vkaf283.1870

Back

Immunity and protection following an H5N1-based polyanhydride nanoparticle IAV vaccine 4152

Abstract

Open access

Peer reviewed

Immunity and protection following an H5N1-based polyanhydride nanoparticle IAV vaccine 4152

Frederick Tei-Maya, Payton Kahl, Chris Lopez, Kathleen Ross, Jeffery Dubert, Boopathi Sownthirarajan, Balaji Narasimhan, Balaji Manicassamy and Kevin L. Legge

The Journal of immunology (1950), Vol.214(Supplement_1), vkaf2831870

11/01/2025

DOI: 10.1093/jimmun/vkaf283.1870

Files and links (1)

url

https://doi.org/10.1093/jimmun/vkaf283.1870View

Published (Version of record) Open Access

Abstract

Abstract Description Highly pathogenic avian influenza (HPAI) H5N1 influenza virus (IAV) has led to numerous outbreaks in animals and more recently humans within the US. Currently, IAV vaccines are designed to generate antibodies against strain-specific IAV hemagglutinin. In contrast, the induction of T cell immunity after current IAV vaccines is minimal or limited. Importantly, existing memory T cells are known to be important in protection against heterologous IAV infections. Our prior work has shown that our polyanhydride IAV vaccine (IAV-nanovax), in contrast to existing IAV vaccines, induces robust T and B cell immunity and protection against homologous and heterologous IAV. Therefore, we examined the immunity and protection afforded by a new H5N1 based nanoparticle vaccine (i.e. H5-nanovax) in comparison to our H1N1 based vaccine (i.e. IAV-nanovax H1). Our findings show that in contrast to naïve mice, mice administered the H5-nanovax were protected from morbidity and mortality when challenged with either the HPAI and low path forms of H5N1. Interestingly, H1-nanovax also reduced morbidity and mortality after H5 IAV challenge. The protection observed is consistent with our observation of local and systemic immune responses (T cell and B cell) as well as antibodies against IAV after vaccination and before virus challenge. Thus, due to its T cell induction, IAV-nanovax may hold the potential to offer broad-based cross-strain protection against both seasonal and potential pandemic IAV. Funding Sources NIH/NIAID R01AI168001; NIH/NIAID R01AI127565; NIH/NIAID R01AI141196 Topic Categories Vaccines and Immunotherapy (VAC)

Cells - B Cells T Cells Infections - Viral Processes - Memory Tissues - Lung

Details

Title: Subtitle: Immunity and protection following an H5N1-based polyanhydride nanoparticle IAV vaccine 4152
Creators: Frederick Tei-Maya
Payton Kahl
Chris Lopez
Kathleen Ross
Jeffery Dubert
Boopathi Sownthirarajan - University of Iowa
Balaji Narasimhan
Balaji Manicassamy
Kevin L. Legge - University of Iowa
Resource Type: Abstract
Publication Details: The Journal of immunology (1950), Vol.214(Supplement_1), vkaf2831870
DOI: 10.1093/jimmun/vkaf283.1870
ISSN: 0022-1767
eISSN: 1550-6606
Publisher: Oxford University Press
Grant note: NIH/NIAID: R01AI168001, R01AI127565, R01AI141196
NIH/NIAID R01AI168001; NIH/NIAID R01AI127565; NIH/NIAID R01AI141196
Alternative title: IMMUNOLOGY2025™ Abstracts
Language: English
Date published: 11/01/2025
Academic Unit: Dermatology; Microbiology and Immunology; Pathology
Record Identifier: 9985035037202771

Metrics

5 Record Views